We compared the potency of CAR-T cells (anti-CD123-CD20 vs. anti-CD123-GLUT5) by infusing a low dose of 0.5×106 CAR+ T cells intravenously (IV) and measuring tumour burden by bioluminescence at regular intervals. This evidence concerns the gene SLC2A5 and neoplasm.